ClinicalTrials.gg
RecruitingNCT06229288CAPTAINUpdated Nov 19, 2026

Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward

A Phase 3 interventional study of Amoxicillin and Amoxicillin/clavulanate in Community-acquired Pneumonia, sponsored by Nantes University Hospital. Recruiting at 19 sites in France. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Nantes University Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 6 months later.
Updated Nov 19, 20262 sites added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
326
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing amoxicillin in Community-Acquired Pneumonia — 5 open to participants now, 5 under way, 2 of them phase 3. Amoxicillin · Community-Acquired Pneumonia.

Planned enrollment
3rd of 12
326 · median 243
Started
2024
with 2 others
Phase 3
Only one
of the 12
Registered
9th of 12
by date
Lead sponsor
1 of 12
Nantes University Hospital

Among the 12 studies testing amoxicillin in Community-Acquired Pneumonia, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2024, is the only one in phase 3, and was the 9th registered.

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Open to participants now

5 of the 12 studies testing amoxicillin in Community-Acquired Pneumonia are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About amoxicillin

Amoxicillin: first FDA approval 1974 (AMOXIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing amoxicillin in Community-Acquired Pneumonia, or all of them as a file.
02

Study summary

Reduce inappropriate antibiotic use is a priority of public health agencies. Community-acquired pneumonia (CAP) is one of the most important indications for antibiotic prescriptions.

In the majority of the studies of CAP, there is a large proportion of cases with no pathogen identified. Thus, the choice of the empirical antibiotic depends on the most likely pathogen, individual risk factors, comorbidities, and allergies.

Patients aged 65 years or older are often treated with amoxicillin/clavulanate or with another broad-spectrum antibiotic (third-generation cephalosporins, antipneumococcal fluoroquinolone). However, broad-spectrum antibiotic prescription in CAP is debated and concerns exist about side-effects and selective pressure for resistance. Due to lack of head-to-head antibiotic comparisons, a recent Cochrane review concluded that current evidence from Randomized Clinical Trials (RCTs) is insufficient to make evidence-based recommendations for the choice for antibiotic to be used, highlighting an important evidence gap.

Read the detailed description

Thus, the goal of the proposed trial is to compare clinical efficacy and safety of two CAP antimicrobial treatments, amoxicillin and amoxicillin/clavulanate, in patients aged 65 years or older and hospitalized in a non-intensive care unit (ICU) ward. The CAPTAIN study will be a multi-center, randomized, open, non-inferiority trial comparing clinical efficacy at Day 30 among patients ≥65 years of age, and hospitalized in a non-ICU ward, treated with narrow-spectrum (amoxicillin) versus broad-spectrum (amoxicillin/clavulanate) antimicrobial therapy for CAP. This will be a pivotal clinical trial that will provide evidence to inform CAP treatment guidelines.

03

Conditions studied

  • Community-acquired Pneumonia

Keywords

  • Community-acquired pneumonia
  • Amoxicillin
  • Amoxicillin/clavulanate
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient aged 65 years or older with or without comorbidities defined by chronic diseases in immunocompetent patients,
  2. Patient admitted to the hospital for a CAP defined by at least two clinical signs of pneumonia (cough, sputum production, dyspnea, tachypnea, or pleuritic pain, abnormal lung auscultatory sounds, fever (temperature > 38°C) or hypothermia (\<36°C)), and had radiological evidence of a new infiltrate confirming pneumonia
  3. Patient understanding oral and written French
  4. Written obtained from patient prior to participation in the study (if the patient is unable to express in writing: consent by a trusted person).
  5. Patients should be able to call and to answer to a phone call or to be with a relative who can help him to call or to answer questions notably raised by a medical staff belonging to the site

Exclusion criteria

Exclusion Criteria:

  1. Signs of severe CAP (abscess, massive pleural effusion, serious chronic respiratory insufficiency, ICU admission)
  2. Patient requiring ICU admission,
  3. Estimated \< 30 ml/min,
  4. Known (asplenia, neutropenia, agammaglobulinemia, transplant, myeloma, lymphoma, known and CD4\<200/mm3),
  5. Exacerbation of ,
  6. Life-threatening state expected to lead to possible imminent death,
  7. Suspected atypical bacteria requiring combined antibiotics therapy,
  8. Legionella suspected,
  9. Subjects with clinical or epidemiological environment leading to suspect a healthcare associated pneumonia with antibiotic resistant pathogen (including long-term care facility)
  10. Patient known to be colonized with Pseudomonas aeruginosa or Enterobacteriaceae in the respiratory tract,
  11. Suspicion of aspiration pneumonia,
  12. Administration of any antibiotic treatment for more than 24 hours before inclusion,
  13. History of jaundice/hepatic impairment associated with amoxicillin/clavulanate acid,
  14. History of bacterial pneumonia less than 1 month prior to study inclusion
  15. History of or allergy to beta-lactam or to any included in study antibiotics,
  16. Subject without health insurance,
  17. Subject without home address or difficulty in terms of follow-up (vacation, job transfer, geographical distance, lack of motivation),
  18. Patient under judicial protection,
  19. Diagnosis confirmed of SAR-Cov2 infection (PCR Test, covid antigen rapid test, chest computed tomography (CT) scan),
  20. Participation to another interventional study and having an exclusion period that is still in force during the screening phase or expected participation to another interventional study during participation to the CAPTAIN study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
326 participants (estimated)

Study arms

  • Experimental
    Amoxicillin

    Amoxicillin is an antibiotic treatment approved in France and in many countries. The investigational medicinal products (IMPs) are: \- Amoxicillin capsules : Formulated as a 500 mg capsules for PO administration (commercially available). Description in IMP file. Amoxicillin capsules contain compendial excipients listed in the Summary Product Characteristics (SmPC), current version, and are kept in a cool dry place where the temperature stays at 15- 25°C. \- Amoxicillin IV vials : Formulated as a 1000 mg vial for IV administration (commercially available). Description in IMP file. Amoxicillin IV vials contain compendial excipient listed in the Summary Product Characteristics (SmPC), current version, and are kept in a cool dry place where the temperature stays at 15-25°C.

    Drug: Amoxicillin

  • Active comparator
    Amoxicillin/clavulanate

    Amoxicillin/clavulanate is recommended by French and European guidelines for the treatment of patients aged 65 years or older, and hospitalized in a non-ICU ward, as reported above. The active comparators (IMPs) are: \- Amoxicillin/clavulanate tablets: Formulated as a tablet for PO administration (commercially available). Description in IMP file. Tablets contain 500 mg of amoxicillin trihydrate and 62.5 mg of clavulanate. Amoxicillin/clavulanate tablets contain compendial excipients listed in the Summary Product Characteristics (SmPC), current version, and are kept in a cool dry place where the temperature stays at 15-25°C. \- Amoxicillin/clavulanate vials Vials contain 1000 mg of amoxicillin and 200 mg of clavulanate. Description in IMP file. Amoxicillin/clavulanate vials contain compendial excipients listed in the Summary Product Characteristics (SmPC), current version, and are kept in a cool dry place where the temperature stays at 15-25°C

    Drug: Amoxicillin/clavulanate

Interventions

  • Participants will be randomized to IV/oral amoxicillin or IV/oral amoxicillin/clavulanate for 5 days. Both agents are approved for treatment of respiratory infections. Amoxicillin PO: The dose is two capsule of 500 mg every 8 hours (that is 3 times daily). Amoxicillin IV: The dose is 1 g every 8 hours (that is 3 times daily)

    Also known as: Experimental drug

  • DrugAmoxicillin/clavulanate

    Drug pages: AmoxicillinStudies of AmoxicillinAmoxicillin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Clavulanic AcidStudies of Clavulanic AcidClavulanic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will be randomized to IV/oral amoxicillin or IV/oral amoxicillin/clavulanate for 5 days. Both agents are approved for treatment of respiratory infections. Amoxicillin/clavulanate PO: The dose is two tablets of 500 mg/62.5 mg every 8 hours (that is 3 times daily, approved standard dose) Amoxicillin/clavulanate IV: The dose is 1 g/200 mg every 8 hours (that is 3 times daily, approved standard dose)

    Also known as: active comparator drug

06

What researchers measure

Primary outcomes

  1. Non-inferiority

    To investigate non-inferiority in terms of clinical efficacy among patients aged 65 years or older, hospitalized in a non-ICU ward for a CAP, and treated with narrow-spectrum (amoxicillin) versus broad-spectrum (amoxicillin/clavulanate) antimicrobial therapy, at Day 30 since hospital admission. To answer this question, clinical success rate at Day 30 since admission, defined as survival after completion of antibiotic treatment course, resolution of signs and symptoms of the infection (cough, purulent sputum production, dyspnea, or pleuritic chest pain) present at baseline with no new symptoms or complications attributable to CAP and no need for further antibacterial therapy will be determined

    Time frame: Day 30 after inclusion (=Day 1)

Secondary outcomes

  1. Rates of early clinical response

    Early clinical response will be defined as survival with improvement of one or more levels relative to baseline in two or more symptoms of CAP and no worsening of one or more levels in other symptoms of community-acquired bacterial pneumonia, without receipt of rescue antibacterial therapy

    Time frame: Day 3 after inclusion (=Day 1)

  2. Clinical cure after the end of treatment

    The proposed endpoint of clinical cure after the end of treatment is defined as resolution in relevant signs and symptoms reported at baseline, no worsening of symptoms, and no change in antimicrobial regimen

    Time frame: Within 30 days after inclusion (=Day 1) compared to baseline

  3. To investigate total duration of antibiotic treatment, i.e., the total number of days with antibiotics during the Day 30 follow-up after hospital admission

    Days taking antibiotics from the first dose until the interruption of any antibiotic treatment during hospitalization and at late follow-up at Day 30 after hospital admission (to identify the use of any other antibiotic after hospital discharge defined as no IV, regain of autonomy identical to baseline, good clinical response and favorable evolution following initiation of antibiotics, other criteria left at the discretion of the investigators according to centers' practices)

    Time frame: Day 30 after inclusion (=Day 1)

  4. To investigate all-cause mortality at Day 30 after hospital admission

    All-cause mortality at Day 30 after hospital admission

    Time frame: Day 30 after inclusion (=Day 1)

  5. To investigate the rate of polymerase chain reaction (PCR)-positive Clostridium difficile among patients with diarrhea

    Number of positive polymerase chain reaction (PCR)-positive Clostridium difficile among patients with diarrhea

    Time frame: Within 30 days after inclusion (=Day 1)

  6. To investigate in-hospital mortality

    Number of deaths during hospitalization

    Time frame: Within 30 days after inclusion (=Day 1)

  7. To investigate ICU transfer during the Day 30 follow-up

    Number of patients transferred to the ICU during the Day 30 follow-up

    Time frame: Day 30 after inclusion (=Day 1)

  8. To investigate CAP recurrence and hospital readmissions up to day 30 from hospital admission

    Number of hospital readmissions and CAP recurrence up to day 30 from hospital admission

    Time frame: Day 30 after inclusion (=Day 1)

  9. To investigate adverse events attributable to antibiotics up to day 30 from hospital admission

    Number of adverse events attributable to antibiotics and number of days with adverse events up to day 30 from hospital admission

    Time frame: Day 30 after inclusion (=Day 1)

  10. To investigate compliance with the antibiotic treatment

    Number of days of antibiotic treatment taken

    Time frame: Within 7 days after inclusion (=Day 1)

  11. To investigate length of hospital stay

    Time frame: Within 30 days after inclusion (=Day 1)

  12. Analysis of sensitivity todiscordance

    To investigate the agreement between the early clinical response endpoint and the investigator's clinical judgment: the agreement between early clinical response (main endpoint) and the investigator's clinical judgement (clinical success or clinical failure) will be assessed

    Time frame: Within 30 days after inclusion (=Day 1)

07

Study locations

19 of 19 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for May 2027, 37 months after the start.

Of 20 phase 3 interventional studies under Community-Acquired Pneumonia, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 64. This study's planned 37 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2024
First posted
Jan 29, 2024
StartActual
Apr 25, 2024
Primary completionEst.
May 25, 2027
CompletionEst.
May 25, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 France)
  • CH Saint-Nazaire · Saint-Nazaire, France
  • CH Saint-Nazaire · Saint-Nazaire, France
Show 2 removed
  • CH Saint-Nazaire · Saint-Nazaire, France
  • CH Saint-Nazaire · Saint-Nazaire, France
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 France)
    • CH Saint-Nazaire · Saint-Nazaire, France
    • CH Saint-Nazaire · Saint-Nazaire, France
    Show 2 removed
    • CH Saint-Nazaire · Saint-Nazaire, France
    • CH Saint-Nazaire · Saint-Nazaire, France
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06229288
Responsible party
Sponsor
First posted
Jan 29, 2024
Start date
Apr 25, 2024
Primary completion
May 25, 2027 (estimated)
Completion
May 25, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Emmanuel MONTASSIER, Professor
Contact
emmanuel.montassier@chu-nantes.fr
02 53 48 20 38 ext. +33
Frederic BALEN, Doctor
principal investigator · Toulouse UH
Guillaume MARTIN-BLONDEL, Doctor
principal investigator · Toulouse UH
Perrine DUMANOIR, Doctor
principal investigator · Grenoble Hospital
VIGLINO Damien, Doctor
principal investigator · Grenoble Hospital
Alexandrine VIDAL, Doctor
principal investigator · Perigueux Hospital
Delphine PLARD, Doctor
principal investigator · Angers UH
Rafaël MAHIEU, Doctor
principal investigator · Angers UH
Anne-Laure FERAL-PIERSSENS, Doctor
principal investigator · Avicenne AP-HP
Frederic MECHAI, Doctor
principal investigator · Avicenne AP-HP
Aurelie DAUMAS, Professor
principal investigator · Marseille Timone Hospital
Dominique MERRIEN, Doctor
principal investigator · Centre Hospitalier Departemental Vendee
Sylvain LE GENTIL, Doctor
principal investigator · Centre Hospitalier Departemental Vendee
Pierre BARSI, Doctor
principal investigator · Vannes Hospital Bretagne Atlantic
Rozenn LE BERRE, Doctor
principal investigator · Brest Hospital
Sylvain JAFFUEL, Doctor
principal investigator · Brest Hospital
Xavier DUBUCS, Doctor
principal investigator · Toulouse UH
Matthieu THIBAULT, Doctor
principal investigator · Saint-Nazaire Hospital
BOISSEAU Dorothée, Doctor
principal investigator · Saint-Nazaire Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amoxicillin

Start the discussion